# Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

> **NCT04414540** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Trisha Wise-Draper** · enrollment: 21 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Metformin Extended Release Oral Tablet
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04414540
- **Lead sponsor:** Trisha Wise-Draper
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-31
- **Primary completion:** 2026-02-02
- **Final completion:** 2026-09-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04414540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04414540, "Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04414540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*